UK Car Lending

Disruptive COVID-19 influences Malaysian auto industry, 2021



Globe Newswire

Trinity Biotech plc Reports First Quarter Fiscal 2021 Financial Results

Conference call scheduled for May 25, 2021 at 11:00 a.m. EASTERNDUBLIN, Ireland, May 19, 2021 (GLOBE NEWSWIRE) – Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for point-of-sale markets Care and Clinical Laboratories, will report first quarter fiscal 2021 financial results on Tuesday, May 25, 2021. The company has scheduled a same-day conference call, Tuesday, May 25, 2021 at 11:00 a.m.ET (4:00 p.m. ET). BST) to discuss the results for the quarter. Interested parties can access the call by dialing the following number: US Toll Free: 1-844-861-5499 International Toll: 1-412-317-6581 Ireland Toll: 014311269 Ireland Toll Free: 1800932830 Please ask to be reached to Trinity Biotech call. A simultaneous webcast of the call can be viewed at: https: //services.choruscall.com/mediaframe/webcast.html? Webcastid = VZlwzsvY A replay of the call is available until June 1, 2021 by dialing: US Toll Free: 1-877-344-7529 International Toll: 1-412-317-0088 Replay Code: 10156870 To access the replay using an international call number, please see the link below: https: //services.choruscall.com/ccforms /replay.html A webcast of the call will be available for 30 days at: https: //services.choruscall.com/mediaframe/webcast.html?webcastid=VZlwzsvY Replays will be available 1 hour after the end of the conference. Certain statements made in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “estimate”, “plan”, “intend”, “expect” , “Believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause Trinity Biotech’s actual results, performance or achievements to differ materially from future results, performance or achievements that could be expressed or implied by such forward-looking statements, including, but not limited to , search results. and development efforts, risks associated with the epidemic and global spread of the coronavirus (COVID-19), the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, commercialization of product development and technological difficulties. For further information regarding these and other risks and uncertainties associated with the business of Trinity Biotech, reference is made to our reports filed from time to time with the United States Securities and Exchange Commission. We assume no obligation to update or revise forward-looking statements for any reason. Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, comprising both reagents and instruments, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of hemoglobin A1c and other chemical parameters in serum, plasma and whole blood. Trinity Biotech sells directly to the United States, Germany, France and the United Kingdom and through a network of international distributors and strategic partners in more than 75 countries around the world. For more information, please visit the company’s website: www.trinitybiotech.com. Contact John Gillard Trinity Biotech plc (353) -1-2769800 Joe Diaz Lytham Partners, LLC Investor Relations (1) -602-889-9700 E-mail: [email protected]



Leave a Reply

Your email address will not be published.